Cargando…
Patients With Type 2 Diabetes Mellitus and Heart Failure Benefit More From Sodium-Glucose Cotransporter 2 Inhibitor: A Systematic Review and Meta-Analysis
BACKGROUND: Patients with type 2 diabetes mellitus (T2DM) and heart failure (HF) are at higher risk of mortality and hospitalization for heart failure (HHF). A recent study showed that sodium-glucose cotransporter 2 (SGLT-2) inhibitors may be a promising choice. METHODS: We searched the PubMed, Emba...
Autores principales: | Chen, Chengcong, Peng, Hong, Li, Mingzhu, Lu, Xiyan, Huang, Miao, Zeng, Yongmei, Dong, Guoqing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8572881/ https://www.ncbi.nlm.nih.gov/pubmed/34759887 http://dx.doi.org/10.3389/fendo.2021.664533 |
Ejemplares similares
-
Renal outcomes with sodium-glucose cotransporters 2 inhibitors
por: Sun, Xiaoya, et al.
Publicado: (2022) -
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Benefits Versus Risk
por: Jasleen, Bains, et al.
Publicado: (2023) -
The Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Sympathetic Nervous Activity
por: Wan, Ningning, et al.
Publicado: (2018) -
Sodium Glucose Cotransporter 2 Inhibitors Reduce the Risk of Heart Failure Hospitalization in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Zhang, Ailing, et al.
Publicado: (2021) -
Time to Benefit of Sodium-Glucose Cotransporter-2 Inhibitors Among Patients With Heart Failure
por: Chen, KangYu, et al.
Publicado: (2023)